A phase I study of INNO-406 in patients with advanced Philadelphia chromosome-positive (Ph+) leukemias who are resistant or intolerant to imatinib and may have also failed second-generation tyrosine kinase inhibitors
2008 ◽
Vol 26
(15_suppl)
◽
pp. 7018-7018
◽
2019 ◽
2019 ◽
2019 ◽
2020 ◽
2014 ◽
Vol 99
(4)
◽
pp. 513-518
◽